Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06427447
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-19
Brief Title:
Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer ADJUPANC
Sponsor:
Changhai Hospital
Organization:
Changhai Hospital
Study Overview
Official Title:
Adjuvant Chemoradiotherapy Versus Chemotherapy for Post-operative Pancreatic Cancer
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ADJUPANC
Brief Summary:
In this trial we aim to compare the outcomes of adjuvant chemoradiotherapy with chemotherapy for patients with resected pancreatic cancer who are at high risk of disease progressions
Detailed Description:
Pancreatic cancer is a lethal malignancy with the lowest 5-year overall survival rate of 9 and an increasing incidence In China the mortality of pancreatic cancer ranked the sixth among all cancers Although surgical resection is the only radical treatment only less than 20 patients could receive upfront surgery at the initial diagnosis Even though patients have surgery the incidence of disease progressions including local progression and metastasis is about 80-90 In NCCN guidelines and Chinese guidelines adjuvant chemotherapy is recommended for post-operative pancreatic cancer while adjuvant chemoradiotherapy could also be used However it has not been clarified that which patients may benefit from adjuvant chemoradiotherapy and no high-level evidence has shown the advantages of adjuvant chemoradiotherapy over chemotherapy In meta-analyses it was demonstrated that patients with lymph nodes metastases R1 or R2 resection or lymphovascular invasion could achieve longer survival after adjuvant chemoradiotherapy compared with chemotherapy Therefore we aim to compare the outcomes of adjuvant chemoradiotherapy with those of chemotherapy in patients with lymph nodes metastases R1 or R2 resection or lymphovascular invasion after surgical resection of pancreatic cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None